Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

NCT06039202 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: CA102N
DRUG: TAS-102
BIOLOGICAL: Bevacizumab

Sponsor

Holy Stone Healthcare Co., Ltd